Day Three – 18 June 2025 - CEST Time Zone
include?
How does this interact with other pre-existing medical device and ESG legislation?
MDR
Batteries
REACH
- Current adoption status
- Best practices to ensure readiness to comply
With Product Liability Directive 85/374/EEC having been adopted, what does this mean for medical device manufacturers?
What’s changed and what does it mean for liability looking ahead?
How does the directive interact/overlap with other regulations (eg MDR; AI Liability Directive; RAD)?
What should manufacturers be doing now to prepare?
- Harriet Hanks - Counsel, Freshfields Bruckhaus Deringer
- Kristina Weiler - Partner, Freshfields Bruckhaus Deringer
Please contact: Neha Singh– neha.singh@informa.com If you are interested in participating as a speaker, panelist, moderator or hosting a webinar
- Roberto Girardi - Senior Director, Global Head of Privacy Compliance & Risk Management, ResMed
Please contact: Neha Singh– neha.singh@informa.com If you are interested in participating as a speaker, panelist, moderator or hosting a webinar
A year on from the decision by the Hanseatic Higher Regional Court Hamburg (OLG Hamburg, file reference: 3 U 3/24) regarding telemedicine app – where are we now?
Competition law and advertising considerations
How can this situation be avoided?
Importance of accurate qualification and classification of software and apps
- Hilary Jones - Vice President Legal - Global Commercial and Regulatory Law, BioNTech UK Limited
- Michele Boggiani - Director, Global Legal Lead, Galderma
- Jacqueline Mulryne - Partner, Arnold & Porter
Summary of the case
Process of original ruling and subsequent appeal
Grounds of appeal
Outcome of case for both RRR and BSI
Lessons to takeaway for manufacturers and notified bodies
- Alex Denoon - Partner, Bristows LLP
- Darren Thain - Director, Global Regulatory Affairs Policy and Intelligence, Smith & Nephew
From a legal perspective, what is the state of play and what are the main elements of new proposals?
Where will the respective proposals take us and are they a route forward?
What would it mean for all stakeholders if the proposals are adopted and do they solve all problems?
- Erik Vollebregt - Partner, Axon Lawyers